You are here

Press Release Archive

 
- Pfizer And Epocrates Partner To Give Healthcare Providers Access To Medical Information Specialists For Medication Questions

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Epocrates, Inc., today announced a collaboration to give healthcare providers (HCPs) mobile access to the Pfizer Medical Information Group to obtain scientific answers to their product questions or to report an adverse event. For the first time, clinicians can make direct contact through the Epocrates drug reference app on their iPhone® device to pharmaceutical manufacturers and immediately apply

 
- Pfizer Announces EMPHASIS-HF Trial To Halt Recruitment Due To Significant Benefit Observed In Patients Treated With Inspra® (Eplerenone)

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial’s independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined

 
- Pfizer Appoints Mikael Dolsten President Of Worldwide Research And Development

(BUSINESS WIRE)--Today, Pfizer Inc. named Mikael Dolsten, M.D., PhD, President of Pfizer Worldwide Research and Development, as the Company completes its integration of these functions following the Wyeth acquisition. Dr. Dolsten previously led Wyeth’s Research and Development organization from May 2008, and after the close of the Wyeth acquisition was named President of Pfizer’s BioTherapeutics Research & Development. Prior to his

 
- Pfizer Animal Health Expands Global Commitment To A Safe Food Supply With A New Focus On Healthy Fish

(BUSINESS WIRE)--Pfizer Animal Health today announced its acquisition of Microtek International, Inc., a recognized innovator in aquaculture vaccines, R&D and healthcare diagnostic services. The acquisition further expands Pfizer’s commitment to a safe food supply from healthy beef and dairy cattle, swine, poultry and, now, fish. Total global fish production – largely for human consumption – now exceeds that of pork, poultry,

 
- Pfizer Oncology To Present New Clinical Data From Ten Molecules Across Multiple Tumor Types

(BUSINESS WIRE)--Pfizer Oncology will present new data highlighting the company’s focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology (ASCO) meeting in Chicago from June 4-8. “Pfizer Oncology is committed to applying discoveries from cancer biology and genetics to the development of new

 
- Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Jean-Michel Halfon, President and General Manager, Emerging Markets, at the Citi 2010 Global Healthcare Conference on Wednesday, May 26, 2010, at 10:30 a.m. Eastern Daylight Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Citi 2010 Global HealthcarConference” link

 
- Pfizer Global Manufacturing Announces Plans To Reconfigure Its Global Plant Network

(BUSINESS WIRE)--Pfizer Global Manufacturing announced today plans to reconfigure its worldwide plant network to create a fully aligned manufacturing and supply organization from the combined networks of Pfizer and Wyeth. This implementation of the first phase of Pfizer’s previously announced Plant Network Strategy includes recommendations to cease operations at eight manufacturing sites in Ireland, Puerto Rico, and the United States by the

 
- Pfizer, Washington University Announce Groundbreaking Collaboration

(BUSINESS WIRE)--In a first-of-a-kind collaboration between academia and industry, Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds. Under the five-year agreement announced today, Pfizer will provide $22.5 million

 
- Pfizer Animal Health Announces First Recipients of New $2 Million Veterinary Scholarship Program

(BUSINESS WIRE)--Pfizer Animal Health announced today the first recipients of a new $2 million scholarship program for U.S. veterinary students. The initiative, designed to support the future of the veterinary profession, will provide up to $2 million in scholarships over its first three years. Administered in partnership with the American Veterinary Medical Foundation (AVMF), the program is an opportunity for Pfizer Animal Health to

 
- Pfizer Reports First-Quarter 2010 Results; Reaffirms 2010 Financial Guidance

BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE): First-Quarter 2010 Revenues of $16.8 Billion First-Quarter 2010 Reported Diluted EPS(1) of $0.25, Adjusted Diluted EPS(2) of $0.60 Reaffirms 2010 Financial Guidance and 2012 Diluted EPS Target Ranges Continues to Make Solid Progress on the Wyeth Integration ($ in millions, except per share

 
- Pfizer Discontinues Phase 3 Trial of Sutent® in Advanced Hepatocellular Carcinoma

(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma (HCC), or liver cancer. Following a review by the independent Data Monitoring Committee (DMC), the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the

 
- Pfizer Hosts Annual Meeting Of Shareholders; Declares 18-Cent Second-Quarter 2010 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared an 18-cent second-quarter 2010 dividend on the company’s common stock, payable June 1, 2010, to shareholders of record at the close of business on May 7, 2010. The second-quarter 2010 cash dividend will be the 286th consecutive quarterly dividend paid by Pfizer. At the company’s Annual Meeting of Shareholders, Chairman and Chief Executive Officer

 
- Pfizer Invites Public To Listen To Webcast Of April 22 Annual Meeting Of Shareholders

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. Eastern Daylight Time on Thursday, April 22, 2010. To access the Webcast, visit the Website at www.pfizer.com and click on the “Annual Meeting of Shareholders” Webcast link on the homepage. Information on accessing and pre-registering for the Webcast will be available at www.pfizer.com

 
- Stemgent and Pfizer Announce Collaboration

(BUSINESS WIRE)--BOSTON

 
- Pfizer Oncology To Present Over 30 Abstracts On Pre-Clinical And Clinical Research At The American Association For Cancer Research Annual Meeting

(BUSINESS WIRE)--Pfizer Oncology announced today that it will present new data from the company’s pipeline, including two novel, dual PI3K/mTOR (phosphatidylinositol 3-kinase / mammalian target of rapamycin) inhibitors (PF-046915021 and PKI-587, also known as PF-05212384);2 crizotinib (PF-02341066), an ALK (anaplastic lymphoma kinase) inhibitor that also inhibits c-MET (c-mesenchymal-epithelial transition factor);3 and PF-04605412, an

 
- Pfizer And Acacia Living Partner To Support Seniors In Living Independently

(BUSINESS WIRE)--Pfizer Inc. and Acacia Living, Inc. (Acacia) announced today they have entered into a strategic alliance to develop an innovative holistic technology solution dedicated to helping seniors age positively and independently. Acacia Living is developing an at-home assisted living connectivity platform to support the ability of a growing aging population to live independently, by improving what Acacia calls access to C.A.

 
- Pfizer Posts Details About Interactions With U.S. Physicians, Other Healthcare Professionals And Clinical Research Partners

(BUSINESS WIRE)--Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare

 
- Pfizer Invites Public to View and Listen to Webcast of May 4 Conference Call with Analysts

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 4, 2010. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2010 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.